Retatrutide vs Mounjaro (Tirzepatide): What the Research Actually Shows
If you have been reading about retatrutide, you have almost certainly seen it compared with Mounjaro. It is a fair question, because the two compounds are closely related. They also differ in one important way. This page sets out, in plain English, how they compare, what the published trials reported, and why a straight answer to “which is better?” does not exist yet.
For in vitro research use only. This page summarises published research for information. It is not medical advice. We do not sell Mounjaro, pens or any product for human use.
The short answer
Mounjaro is the brand name for tirzepatide, which acts on two hormone receptors: GIP and GLP-1. Retatrutide was developed after tirzepatide and acts on the same two receptors plus a third, the glucagon receptor. That extra receptor is the main difference between them.
In separate trials, retatrutide produced larger average changes in body weight than tirzepatide did in its own trials. Those trials used different people, doses and durations, though, so the numbers cannot simply be put side by side. A direct head-to-head study (TRIUMPH-5) is running, but its results have not been published. Until they are, nobody can say for certain that one is “better”.
Mounjaro and tirzepatide: the same compound
A lot of confusion comes from the names. Mounjaro is a brand. Tirzepatide is the compound inside it. When people search for “retatrutide vs Mounjaro” or “retatrutide vs tirzepatide”, they are asking the same question.
Retatrutide has no brand name yet, because it has not been approved anywhere. During development it is known by its code, LY3437943. Tirzepatide’s development code was LY3298176. Both come from the same developer, and retatrutide is often described as the next step on from tirzepatide.
Two receptors vs three: the real difference
Both compounds work by imitating natural gut hormones that the body releases after eating. The difference is how many of those hormone signals each one copies.
- GLP-1 receptorTargeted by both. GLP-1 signalling is linked to insulin release, slower stomach emptying and appetite signals in the brain.
- GIP receptorTargeted by both. GIP is a second gut hormone involved in insulin release and fat metabolism.
- Glucagon receptorTargeted by retatrutide only. Glucagon signalling is studied for its effects on energy expenditure and liver fat.
That is why tirzepatide is called a dual agonist and retatrutide a triple agonist. Researchers are particularly interested in whether adding glucagon activity changes outcomes such as liver fat. A phase 2a study on liver fat was published in 2024.
Side-by-side comparison
| Retatrutide | Tirzepatide (Mounjaro) | |
|---|---|---|
| Receptor targets | GIP, GLP-1 and glucagon | GIP and GLP-1 |
| Type | Triple agonist | Dual agonist |
| Development code | LY3437943 | LY3298176 |
| Length | 39 amino acids | 39 amino acids |
| Half-life extension | C20 fatty diacid (albumin binding) | C20 fatty diacid (albumin binding) |
| Molecular weight | ≈ 4731 g/mol | ≈ 4814 g/mol |
| CAS number | 2381089-83-2 | 2023788-19-2 |
| Development stage | Phase 3 (TRIUMPH programme) | Approved prescription medicine |
| UK licence | None | MHRA authorised, prescription only |
What the trials reported
This is the part most people are looking for. The figures below are the average change in body weight reported in each trial’s published or announced results, which is the main thing these studies measure. They describe what happened in those trial populations. They are not a prediction for anyone else.
| Trial | Compound | Length | Reported result (highest dose) |
|---|---|---|---|
| SURMOUNT-1 (phase 3) | Tirzepatide | 72 weeks | −20.9% vs −3.1% on placebo |
| Phase 2 obesity trial | Retatrutide | 48 weeks | −24.2% vs −2.1% on placebo |
| TRIUMPH-1 (phase 3) | Retatrutide | 80 weeks | −28.3% vs −2.2% on placebo |
| TRIUMPH-2 (phase 3, with type 2 diabetes) | Retatrutide | 80 weeks | −20.8% vs −4.0% on placebo |
| TRIUMPH-3 (phase 3, with heart disease) | Retatrutide | 80 weeks | −22.6% vs −3.2% on placebo |
It is tempting to read this table and conclude that retatrutide “wins”. Be careful. SURMOUNT-1 ran for 72 weeks and TRIUMPH-1 for 80. The people enrolled were different, and so were the doses and the ways the results were analysed. Results from separate trials point in a direction, but they are not a fair contest. The TRIUMPH-1 figures also come from the developer’s announcement in May 2026, and the full peer-reviewed paper is still to come.
Is there a head-to-head trial?
Yes, but it has not finished. TRIUMPH-5 (NCT06662383) is a phase 3, randomised, double-blind trial that compares retatrutide directly with tirzepatide. It is planned to enrol around 800 adults and to run for about 80 weeks. Its main measure is the percentage change in body weight.
Until TRIUMPH-5 reports, the developer’s own position is that no phase 3 head-to-head comparison has been completed. Any website that tells you definitively which compound is stronger is getting ahead of the evidence.
Side effects reported in trials
In trials of both compounds, the most common side effects were gastrointestinal: nausea, diarrhoea, constipation and vomiting. These were more frequent at higher doses and were mostly described as mild to moderate.
Retatrutide’s trials also reported things researchers are watching closely:
- Heart rate: the phase 2 trial reported a dose-dependent rise in heart rate, which peaked around week 24.
- Dysesthesia (unusual skin sensations): reported in up to about 12.5% of people on the highest dose in TRIUMPH-1, against 0.9% on placebo.
- Stopping because of side effects: 11.3% at the highest dose in TRIUMPH-1, against 4.9% on placebo.
We include this so the comparison is honest, not one-sided. A full safety picture for retatrutide will only emerge once the complete phase 3 results are published and reviewed by regulators.
UK status: one is licensed, one is not
Mounjaro (tirzepatide) is authorised by the MHRA and available on prescription in the UK, both privately and, for some patients, on the NHS following NICE guidance. It should only be used under medical supervision.
Retatrutide is not licensed anywhere. It cannot be prescribed in the UK. In July 2026 the developer said it plans to apply to the US regulator in the first quarter of 2027, and no UK timeline has been given. Anything sold as a retatrutide pen or injection for personal use is unlicensed. For more on this, see our Retatrutide UK guide.
Why researchers study both
In the lab, the two compounds answer different questions. Tirzepatide is the established reference for dual GIP/GLP-1 receptor activity. Retatrutide is used to study what happens when glucagon receptor activity is added on top. Studying them together helps isolate the effect of that third receptor.
Sterling Peptides supplies both as research-grade lyophilised peptides from UK stock. Every batch is purity tested by Janoshik, an independent laboratory, using HPLC. They are for in vitro research only.
We do not sell Mounjaro or pens
We do not sell Mounjaro, branded medicines, pens or anything intended for human use. Our compounds are laboratory reagents supplied as powder in sealed vials, for in vitro research only.
Further reading
Frequently asked questions
Is retatrutide better than Mounjaro?
Nobody can say yet. In separate trials retatrutide showed larger average changes in body weight, but those trials differed in length, doses and participants. The direct comparison trial, TRIUMPH-5, has not reported results.
Is retatrutide the same as Mounjaro?
No. Mounjaro is the brand name for tirzepatide, which acts on the GIP and GLP-1 receptors. Retatrutide is a different compound that acts on those two receptors and the glucagon receptor as well.
What is the difference between retatrutide and tirzepatide?
Tirzepatide is a dual agonist (GIP and GLP-1). Retatrutide is a triple agonist (GIP, GLP-1 and glucagon). Both are 39-amino-acid peptides with a fatty acid chain that extends their half-life. Tirzepatide is an approved medicine, while retatrutide is still in phase 3 trials.
Is retatrutide stronger than tirzepatide?
Reported average results for retatrutide have been higher, but they come from different trials, so they cannot be compared directly. A fair comparison needs the results of the head-to-head trial, TRIUMPH-5.
Has retatrutide been compared directly with tirzepatide?
A direct comparison is under way. TRIUMPH-5 (NCT06662383) is a phase 3, randomised, double-blind trial of around 800 adults over about 80 weeks. Its results have not yet been published.
Is retatrutide available in the UK like Mounjaro?
No. Mounjaro is MHRA authorised and available on prescription. Retatrutide has no licence in the UK or anywhere else. It is available only as a research-grade reagent for in vitro laboratory use.
Do you sell Mounjaro or retatrutide pens?
No. We do not sell Mounjaro, pens or any product for human use. Sterling Peptides supplies research-grade retatrutide and tirzepatide as lyophilised powder in sealed vials, for in vitro research only.
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389:514–526.
- Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024.
- TRIUMPH-1 topline results, developer announcement, 21 May 2026.
- TRIUMPH-2 and TRIUMPH-3 topline results, developer announcement, 23 July 2026.
- TRIUMPH-5: retatrutide versus tirzepatide in adults with obesity. ClinicalTrials.gov NCT06662383.
All products supplied by Sterling Peptides, the trading name of Sterling Peptides Ltd, are strictly for laboratory research and analytical purposes. They are not for human or veterinary consumption, or for medical, diagnostic, therapeutic or veterinary use. This page summarises published research and is not medical advice. Questions: contact@sterling-research.com

